ClinicalTrials.gg
Not yet recruitingNCT06928883Updated Apr 15, 2025

Ticin Pilot Study: Sirolimus-Eluting Balloon for Stabilization and Regression of Non-Obstructive Coronary Plaques.

An interventional study of Sirolimus drug eluting ballooon therapy and Optimal guidelines-directed medical therapies (GDMT) in Coronary Arterial Disease (CAD), Vulnerable Coronary Plaques and Multivessel Coronary Artery Disease, sponsored by Cardiocentro Ticino. Not yet recruiting at 1 site in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-15.

Sponsored by Cardiocentro Ticino · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Acute Coronary Syndrome with a site in Switzerland — 10 open to participants now, 12 under way, 2 of them phase 3. Acute Coronary Syndrome · Switzerland.

Planned enrollment
28th of 29
24 · median 1,200
Started
2025
with 5 others
No phase
13 of 42
5 open now
Primary completion
2027-09
later than 6 of 11 live
Registered
33rd of 42
by date
Lead sponsor
3 of 42
Cardiocentro Ticino

Among the 42 studies in Acute Coronary Syndrome with a site in Switzerland, this one is the 28th largest by planned enrollment of the 29 interventional ones that give a count, is one of 6 that started in 2025, is one of 13 with no phase, reaches primary completion later than 6 of the 11 other live ones, and was the 33rd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

10 of the 42 studies in Acute Coronary Syndrome with a site in Switzerland are open now. Recruiting first, the newest first:

4 more — sign in →

All 10 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Acute Coronary Syndrome with a site in Switzerland, or all of them as a file.
02

Study summary

The goal of this pilot clinical trial is to evaluate the use of the Selution SLR sirolimus-eluting balloon, in addition to guideline-directed medical therapy (GDMT), for the preventive treatment of non-flow-limiting vulnerable coronary lesions, compared to GDMT alone, in adult patients with multivessel coronary artery disease and a recent acute coronary syndrome (within 90 days).

The main research question is:

Does the use of the Selution SLR sirolimus-eluting balloon in combination with GDMT reduce the progression and vulnerability of non-flow-limiting vulnerable coronary plaques?

Participants will undergo

  • PCI procedure with baseline IVUS-NIRS assessment
  • Follow-up coronary angiography at 6 months with IVUS-NIRS assessment
  • Clinical follow-up at 3, 6, and 24 months after study enrollment
03

Conditions studied

  • Coronary Arterial Disease (CAD)
  • Vulnerable Coronary Plaques
  • Multivessel Coronary Artery Disease
  • Coronary Vessel
  • Acute Coronary Syndromes (ACS)

Keywords

  • Coronary Arterial Disease (CAD)
  • Vulnerable Coronary Plaques
  • Multivessel coronary artery disease
  • Coronary vessel
  • Acute Coronary Syndromes (ACS)
  • Non-flow limiting vulnerable coronary plaques
  • Sirolimus-eluting DEB
  • DEB Selution SLR
  • Guidelines-directed medical therapies (GDMT)
  • IVUS-NIRS
  • MaxLCBI4mm
  • MaxLCBI4mm≥325
  • Lipid Core Burden Index (LCBI)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Potential subjects must fulfill all following inclusion criteria:

  1. Multivessel coronary artery disease with ACS within 90 days prior to inclusion and successful interventional treatment of the culprit lesion
  2. Presence of ≥ 2 de novo non-culprit lesion without hemodynamic relevance in two different coronary vessels (demonstrated either by wire-based or angiography-based coronary physiology) and with MaxLCBI4mm ≥ 325 at baseline IVUS-NIRS
  3. Age ≥ 18 years
  4. Written

Exclusion criteria

Exclusion Criteria:

Patients are not eligible if any of the following applies:

  1. Non culprit lesion involving the left main and/or ostial left coronary artery, ostial left circumflex artery or ostial right coronary artery;
  2. Non-culprit lesion in a previously stented segment (i.e. within 15 mm from the previously implanted stent);
  3. Non-culprit lesion involving small vessel (\<3.0 mm) deemed not suitable to PCI,
  4. Non-culprit lesion located in a bypass graft or in a grafted vessel;
  5. Severe renal impairment (\<15ml/min/1.73m2) or patient on dialysis treatment;
  6. Known pregnancy r breast-feeding patients;
  7. \<2 year due to other severe non-cardiac disease;
  8. Legally incompetent to provide ;
  9. Partecipation in another clinical study with an product
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Sirolimus-eluting DEB (Selution SLR) therapy + Guidelines-directed medical therapy

    Selution SLR sirolimus-eluting balloon additional to guidelines-directed medical therapy for the preventive treatment of non-flow limiting vulnerable coronary lesions

    Device: Sirolimus drug eluting ballooon therapy

  • Active comparator
    Guidelines-directed medical therapy

    Guidelines-directed medical therapy

    Drug: Optimal guidelines-directed medical therapies (GDMT)

Interventions

  • DeviceSirolimus drug eluting ballooon therapy

    Non-flow limiting vulnerable coronary plaques are treated using sirolimus drug eluting balloon therapy additional to guidelines directed medical therapy.

    Also known as: DEB-GDMT

  • DrugOptimal guidelines-directed medical therapies (GDMT)

    Optimal guidelines-directed medical therapies (GDMT) to reduce plaque burden and vulnerability for non-flow limiting vulnerable plaques

06

What researchers measure

Primary outcomes

  1. Absolute change in the IVUS-NIRS derived lipid core burden index (MAXLCBI4mm) between baseline and 6-months follow-up.

    Time frame: Between baseline and 6-months follow-up.

Secondary outcomes

  1. QCA parameter (minimal lumen diameter, MLD, mm) before and after intervention and at follow-up angiography.

    Minimal lumen diameter (MLD, mm) before the intervention, immediately after the intervention and at follow up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.

  2. QCA parameter (maximal diameter stenosis, MaxS,%) before and after intervention and at follow-up angiography.

    Maximal diameter stenosis (MaxS,%) before the intervention, immediately after the intervention and at follow up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.

  3. QCA parameter (reference vessel diameter, RVD, mm) before and after intervention and at follow-up angiography.

    Reference vessel diameter (RVD, mm) before the intervention, immediately after the intervention and at follow up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.

  4. QCA parameter (lesion lenght, LL, mm) before and after intervention and at follow-up angiography.

    Lesion lenght (LL, mm) before the intervention, immediately after the intervention and at follow up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30 days) months follow-up.

  5. QFR parameters before and after the intervention and at follow-up angiography

    Quantitative Flow Ration (QFR) parameters before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  6. IVUS parameter (minimal lumen diameter, MLD, mm) before the intervention, immediately after the intervention and at follow-up angiography.

    Minimal lumen diameter (MLD, mm) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  7. IVUS parameter (minimal lumen area, MLA, mm2) before the intervention, immediately after the intervention and at follow-up angiography.

    Minimal lumen area (MLA, mm2) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  8. IVUS parameter (maximal diameter stenosis, MaxS,%) before the intervention, immediately after the intervention and at follow-up angiography.

    Maximal diameter stenosis (MaxS, %) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  9. IVUS parameter (lumen volume, LV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.

    Lumen volume (LV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  10. IVUS parameter (vessel volume, VV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.

    Vessel volume (VV, mm3) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  11. IVUS parameter (plaque burden, VV-LV) before the intervention, immediately after the intervention and at follow-up angiography.

    Plaque burden (VV-LV) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  12. IVUS parameter (late lumen loss, LLL) before the intervention, immediately after the intervention and at follow-up angiography.

    Late lumen loss (LLL) before the intervention, immediately after the intervention and at follow-up angiography.

    Time frame: pre procedure, immediately after the procedure and at 6(±30days) months follow-up.

  13. IVUS parameter (acute gain) before the intervention and immediately after the percutaneous intervention.

    Acute gain before the intervention (T0) and immediately after the percutaneous intervention (Tf).

    Time frame: pre procedure and immediately after the procedure.

  14. IVUS parameter (disease progression) after the final result of index PCI (Tf) and at 6(±30days) month follow-up procedure.

    Variation between the final result of index PCI (Tf) and procedure at 6(±30days) month follow-up (Tc).

    Time frame: immediately after the procedure and at 6(±30 days) months after the index PCI.

  15. Target Lesion Revascularization (TLR)

    Rate of target lesion revascularization (TLR) defined as urgent and non urgent

    Time frame: During hospitalization and at 6(±30days) month follow-up.

  16. Target Vessel Revascularization (TVR)

    Rate of target vessel revascularization (TVR) defined as urgent and non-urgent.

    Time frame: During hospitalization and at 6(±30days) month follow-up.

  17. Target Vessel Failure (TVF)

    Rate of target vessel failure, defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization.

    Time frame: During hospitalization and at 6(±30days) month follow-up.

  18. Individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization)

    Rate of the individual components of the composite target vessel failure (TVF) endpoint (defined as cardiac death, target-vessel myocardial infarction and any target lesion revascularization).

    Time frame: During hospitalization and at 6(±30days) month follow-up.

  19. Major adverse cardiac events (MACE) defined as cardiac death, any myocardial infarction and any revascularization.

    Rate of major adverse cardiac events (MACE) defined as cardiac death, any myocardial infarction and any revascularization .

    Time frame: 6(± 30 days) months after the index PCI.

  20. The individual components of the composite major adverse cardiac events (MACE- defined as cardiac death, any myocardial infarction and any revascularization).

    Rate of the individual components of the composite MACE endpoint (defined as cardiac death, any myocardial infarction, any revascularization).

    Time frame: 6(± 30 days) months after the index PCI.

  21. Stroke

    Rate of stroke.

    Time frame: 6(± 30 days) months after the index PCI.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — The final study data will be disseminated to the scientific community through the publication of results in peer-reviewed journals, ensuring accessibility to researchers and healthcare professionals.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2025; primary completion for Sep 2027, 29 months later.

Of 213 non-industry interventional studies with no phase under Acute Coronary Syndrome, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 46. This study's planned 29 months is below that.

Counting every sponsor, half of 228 studies reached it within 34 months; a quarter within 17 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2025
First posted
Apr 15, 2025
StartEst.
Apr 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2028
Last update
Apr 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06928883
Lead sponsor
Cardiocentro Ticino
Responsible party
Marco Valgimigli (Prof. Dr. Med. Marco Valgimigli, Deputy Chief, Cardiocentro Ticino) — Principal investigator
First posted
Apr 15, 2025
Start date
Apr 2025 (estimated)
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Apr 15, 2025

Study contacts

Marco Valgimigli Marco Valgimigli, MD, PhD
Contact
marco.valgimigli@eoc.ch
+41 (0) 91 811 51 11
Enrico Frigoli Frigoli, MD, MHS
Contact
enricofrigoli@eoc.ch
+41 (0) 91 811 51 11

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion